Prolight Diagnostics have appointed G&H | ITL for the development of its innovative point-of-care system, Psyros. The development project started in early 2023 and is steadily progressing. BioStock reached out to G&H’s CEO Charlie Peppiatt and Prolight Diagnostics’ Head of Engineering, Paul Monaghan, to gain further insight into the current status of development.
Read the full article at: https://www.biostock.se/en/2024/04/prolight-diagnostics-collaboration-with-gh-itl-propels-development/
For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: info@prolightdx.com
Telephone: +46 73 582 39 87
Website: www.prolightdx.com/en/
About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.